Navigation Links
Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
Date:1/5/2009

LAVAL, QC, Jan. 5 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Tuesday, January 6, 2009 at 8:30 a.m. (ET) to discuss the U.S. Food and Drug Administration's (FDA) approval of its once-daily formulation of tramadol, RYZOLT(TM). Joining Mr. James R. Howard-Tripp, President and Chief Executive Officer of Labopharm Inc., will be John H. Stewart, President and Chief Executive Officer of Purdue Pharma L.P., Labopharm's marketing partner for RYZOLT in the United States.

To access the conference call by telephone, dial 416-644-3414 or 1-800-733-7560. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Tuesday, January 13, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21293677 followed by the number sign.

A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... , ... Breast Surgeon, Dr. Dennis Holmes of 90210 Surgery Medical Center will ... it fits in the treatment paradigm at Susan G. Komen San Diego’s Annual Dinner ... leading cancer and wellness experts to share the latest innovations in breast cancer research, ...
(Date:3/1/2017)... ... 2017 , ... Award-winning medical group Allied Anesthesia today announced that, as of ... averaging more than one trip per year since 1998. Char was named the Los ... the details of his charitable work. Char has been an Allied Anesthesiologist since 2000. ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... ... pledge to help increase colorectal cancer screening rates by supporting the 80% by ... Control and Prevention (CDC) and the National Colorectal Cancer Roundtable (an organization co-founded ...
(Date:3/1/2017)... ... March 01, 2017 , ... March 2017 – All year ... people don’t want to stop training to brave the cold weather, snow or ice. ... a small incline can help protect these vulnerable joints, says orthopaedic surgeon Kevin D. ...
(Date:3/1/2017)... , ... March 01, 2017 , ... “There is Comfort ... she gave to the author in their all-too-brief time together, and the soul-healing comfort ... the Soul” is the creation of published author, Jerie A. Tau, a dog-loving medical ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... BRENTWOOD, Tenn. , March 1, 2017  Numotion, ... has announced the availability of Tek RMD ("robotic mobilization ... States . Tek RMD is a motorized standing ... are in a manual wheelchair to complete everyday activities ... board and control a Tek RMD unassisted. Numotion is ...
(Date:3/1/2017)... ... Research and Markets has announced the addition of the ... The Global Infertility Therapy Partnering Terms and Agreements ... agreements entered into by the world,s leading healthcare companies. ... deals are discovery or development stage whereby the licensee obtains a ...
(Date:3/1/2017)... MUMBAI, India and PRINCETON, ... Pharmaceutical Industries Ltd (Reuters: SUN.BO, Bloomberg: SUNP IN, ... its subsidiaries or associate companies) today announced that ... Phase-3 clinical trials (reSURFACE 1 and 2) of ... the treatment of moderate-to-severe plaque psoriasis, will be ...
Breaking Medicine Technology: